David Wurtman, MD, MBA
Dr. Wurtman has served as President & CEO of Lyric Pharmaceuticals, an ICU therapeutic development company which he founded, built and successfully funded, and as CMO and an early employee of Lucid Diagnostics, a medical device-diagnostic company which went public via IPO in 2021.
He has led or advised on ~30 in-licensing, out-licensing and co-development deals and M&A transactions and has raised over $70MM from Venture Capital, Private Equity, Family Office and the US Government. He has deep development expertise across drugs, biologics, and diagnostic devices and has led successful FDA interactions, including obtaining FDA Breakthrough designation.
In addition to Lyric and Lucid, Dr. Wurtman has held roles in Corporate, Business and Product Development at Genzyme, Protein Design Labs, Eos Biotechnology, Kineta and Ansun Biopharma. He has consulted to more than 25 biopharmaceutical, technology platform, medical device, diagnostic, and healthcare IT companies on corporate strategy, fundraising, mergers & acquisitions, business development & licensing, product development, market research, product positioning, and clinical-regulatory strategy and development. He has particular expertise in assisting early-stage product and platform companies.
Dr. Wurtman received his AB from Harvard College, MD from Harvard Medical School, and MBA from the MIT Sloan School of Management. Prior to entering the life sciences industry, he completed a primary care internal medicine residency at Mt. Auburn Hospital, a Harvard teaching hospital, and practiced Primary Care at Harvard Community Health Plan as a board-certified physician in Internal Medicine.